Anebulo Pharmaceuticals Inc (ANEB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 06/30
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 11,247 | 14,165 | 16,355 | 19,214 | 14,549 |
| TOTAL | $11,670 | $14,433 | $16,888 | $19,815 | $15,579 |
| Non-Current Assets | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $11,670 | $14,433 | $16,888 | $19,815 | $15,579 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 535 | 571 | 347 | 524 | 381 |
| Accrued Expenses | 534 | 920 | 1,026 | 175 | 132 |
| TOTAL | $1,069 | $1,491 | $1,372 | $698 | $513 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $1,069 | $1,491 | $1,372 | $698 | $513 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 25,633 | 25,633 | 25,633 | 25,633 | 23,369 |
| Common Shares | 26 | 26 | 26 | 26 | 23 |
| Retained earnings | -57,202 | -54,707 | -51,909 | -48,082 | -45,470 |
| TOTAL | $10,601 | $12,942 | $15,516 | $19,117 | $15,067 |
| Total Liabilities And Equity | $11,670 | $14,433 | $16,888 | $19,815 | $15,579 |